La dermocosmétique en appui de traitements oncologiques ciblés.

[en] Some recently introduced targeted treatments in cancerology are responsible for adverse effects on the skin. These events alter the patient well-being. Adequate dermocosmetic management allows to curb the unwanted skin conditions without interfering with the targeted therapeutic effects. However, evidence-based support for using dermocosmetic products as adjunctive cancer treatment remains scarce. It remains nonetheless that the clinical perception is unanimously favourable for such procedure.

Disciplines :

Dermatology

Author, co-author :

FRANCHIMONT, Claudine ; Centre Hospitalier Universitaire de Liège - CHU > Dermatopathologie

Lesuisse, Marianne; Centre Hospitalier Régionale de la Citadelle (Liège) - CHR CITADELLE > Dermatologie

PIERARD, Gérald ; Centre Hospitalier Universitaire de Liège - CHU > Dermatopathologie

Language :

French

Title :

La dermocosmétique en appui de traitements oncologiques ciblés.

Alternative titles :

[en] Dermocosmetology as a support for targeted oncologic treatment.

Publication date :

2014

Journal title :

Revue Médicale de Liège

ISSN :

0370-629X

eISSN :

2566-1566

Publisher :

Université de Liège. Revue Médicale de Liège, Liège, Belgium

Volume :

Issue :

Pages :

35-37

Peer reviewed :

Peer reviewed

Available on ORBi :

since 13 April 2014

Statistics

Number of views

114 (1 by ULiège)

Number of downloads

285 (0 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenAlex citations

Bibliography

Boone SL, Rademaker A, Liu D, et al. - Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results. Oncol, 2007, 72, 152-159. (Pubitemid 351161602)
Piérard GE, Paquet P, C. Piérard-Franchimont C, et al. - Réactions cutanées indésirables à la chimiothérapie et leurs traitements. Rev Med Liège, 2007, 62, 457-462.
Piérard-Franchimont C, Piérard GE. - Réactions cutanées indésirables des traitements par anticorps monoclonaux. Rev Med Liège, 2009, 64, 339-346.
Jacot W, Bessis D, Jorda E, et al. - Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours. Br J Dermatol, 2004, 151, 238-141.
Perez-Soler R, Delord JP, Halpern A, et al.- HER1/EGFR inhibitor-associated rash : future directions for management and investigations outcomes from the HER1/EGFR inhibitor rash management forum. Oncol, 2005, 10, 345-356. (Pubitemid 40647253)
Robert C, Soria JC, Spatz A, et al. - Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol, 2005, 6, 491-500. (Pubitemid 40903630)
Jatoi A, Nguyen PL. - Do patients die from rashes from epidermal growth factor receptor inhibitors? A systematic review to help counsel patients about holding therapy. Oncol, 2008, 13, 1201-1204.
Segaert S, Chiritescu G, Lemmens L, et al. - Skin toxicities of targeted therapies. Eur J Cancer, 2009, 45, 295-308.
Fernandez-Torres R, Martinez Gomez W, Cuevas Santos J, et al. - Rosaceiform eruption induced by cetuximab. Eur J Dermatol, 2010, 20, 392-393.
Haley AC, Calahan C, Gandhi M, et al. - Skin care management in cancer patients : an evaluation of quality of life and tolerability. Supp Care Cancer, 2011, 19, 545-554.
Piérard GE, Piérard-Franchimont C, Humbert P. - Bioimpact of anti-EGFR treatment on the pilosebaceous follicles. Eur J Dermatol, 2012, 22, 54-57.
Dreno B, Bensadoun RJ, Humbert P, et al. - Algorithm for dermocosmetic use in the management of cutaneous side-effects associated with targeted therapy in oncology. J Eur Acad Dermatol Venereol, Epub 2013.
Hermanns JF, Piérard GE, Quatresooz P. - Erlotinib-responsive actinic keratoses. Oncol Rep, 2007, 18, 581-584.
Lynch TJ Jr, Kim ES, Eaby B, et al. - Epidermal growth factor receptor inhibitor-associated cutaneous toxicities : an evolving paradigm in clinical management. Oncol, 2007, 12, 610-621. (Pubitemid 350012125)
Galimont-Collen AF, Vos LE, Lavrijsen AP, et al. - Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors. Eur J Cancer, 2007, 43, 845-851. (Pubitemid 46366684)
Piérard-Franchimont C, Quatresooz P, Reginster MA, et al. - Revisiting cutaneous adverse reactions to pemetrexed. Oncol Letters, 2011, 2, 769-772.
Sabatiello M, Willemaers V, Lesuisse M et al. - Pemetrexed-induced pityriasis lichenoides-like dermatitis. J Eur Acad Dermatol Venereol, 2012, 26, 127-129.
Jatoi A, Green EM, Rowland KM Jr, et al. - Clinical predictors of severe cetuximab-induced rash: observations from 933 patients enrolled in north central cancer treatment group study N0147. Oncology, 2009, 77, 120-123.
Piérard GE, C. Piérard-Franchimont C, Xhauflaire-Uhoda E, et al. - Remedial cosmetics at the crossroads between cosmetology and dermatology. Household Pers Care, 2007, 3, 54-55.
Burtness B, Anadkat M, Basti S, et al. - NCCN task force report : management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer. J Natl Compr Canc Netw, 2009, 7, S5-S21.
Grenader T, Gipps M, Goldberg A. - Staphylococcus aureus bacteriemia secondary to severe erlotinib skin toxicity. Clin Lung Cancer, 2008, 9, 59-60. (Pubitemid 351251603)
Piérard-Franchimont C, Quatresooz P, Rorive A, et al. - How to manage hair changes in cancer patients. In: Handbook of skin care in cancer patients. P. Vereecken, A. Awada (eds). Publ. Nova publishers, New York, 2012, 21-34.
Skolarus TA, Holmes-Rovner M, Northouse LL, et al. - Primary care perspectives on prostate cancer survivorship: Implications for improving quality of care. Urol Oncol, 2011, 18, 21775171.
National Institutes of Health. - National Cancer Institute. Common terminology criteria for adverse events (CTCAE), 2009, version 4.0.
Agero AL, Dusza SW, Benvenuto-Andrade C, et al. - Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol, 2006, 55, 657-670. (Pubitemid 44436627)
Roe E, García Muret MP, Marcuello E, et al. - Description and management of cutaneous side effects during cetuximab or erlotinib treatments: a prospective study of 30 patients. J Am Acad Dermatol, 2006, 55, 429-437. (Pubitemid 44189595)
Hu JC, Sadeghi P, Pinter-Brown LC, et al. - Cutaneous side effects of epidermal growth factor receptor inhibitors : clinical presentation, pathogenesis, and management. J Am Acad Dermatol, 2007, 56, 317-326. (Pubitemid 46091817)
Wohlrab J, Luftner D, Johne A, et al. - The advantage of a proactive, barrier-protective, supportive skin care in patients with breast cancer on chemotherapy. Oncology, 2011, 34, 62.
Piérard-Franchimont C, Quatresooz P, Reginster MA, et al. - Imputabilité médicamenteuse dans les iatrogénies cutanées. Rev Med Liège, 2011, 66, 474-477.